ClinicalTrials.gg
CompletedNCT01219855Updated Aug 25, 2016Results posted

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

A Phase 2/3 interventional study of Cohort 1 CTAP101 Capsules- 60µg and Cohort 1 CTAP101 Capsules - 90µg in Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency, sponsored by OPKO Health, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-08-25.

Sponsored by OPKO Health, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
399th of 819
78 · median 72
Started
2010
with 41 others
Phase 2/3
13 of 988
1 open now
Registered
185th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 399th largest by enrollment of the 819 interventional ones that give a count, is one of 42 that started in 2010, is one of 13 in phase 2/3, and was the 185th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).

03

Conditions studied

  • Chronic Kidney Disease
  • Secondary Hyperparathyroidism
  • Vitamin D Insufficiency

Keywords

  • Parathyroid Diseases
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Hyperparathyroidism, Secondary
  • Vitamin D
  • Hyperparathyroidism
  • Kidney Diseases
  • Kidney Failure
  • Renal Insufficiency, Chronic
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Urinary albumin excretion of ≤3000 μg of creatinine
  2. Stage 3 CKD
  3. Plasma iPTH: > 70 pg/mL and \< 500 pg/mL
  4. Serum Ca: ≥ 8.4 mg/dL and \< 10.0 mg/dL
  5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL
  6. Serum 25-hydroxyvitamin D: > 10 ng/mL and \< 29 ng/mL.
  7. Discontinue vitamin D use for duration of study

Exclusion criteria

Exclusion Criteria:

  1. History of kidney transplant or parathyroidectomy
  2. Spot urine calcium:creatinine ratio > 0.2
  3. Current serious illness, such as , , liver disease, cardiovascular event or hepatitis
  4. Currently on dialysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Cohort 1: CTAP101 Capsules 60µg

    Drug: Cohort 1 CTAP101 Capsules- 60µg

  • Experimental
    Cohort 1: CTAP101 Capsules 90µg

    Drug: Cohort 1 CTAP101 Capsules - 90µg

  • Placebo comparator
    Cohort 1: Sugar Capsule

    Drug: Cohort 1 Matching Sugar Capsule

  • Experimental
    Cohort 2: CTAP101 Capsules 30µg

    Drug: Cohort 2 CTAP101 Capsules - 30µg

  • Placebo comparator
    Cohort 2: Sugar Capsule

    Drug: Cohort 2 Matching Sugar Capsule

Interventions

  • DrugCohort 1 CTAP101 Capsules- 60µg

    60µg of CTAP101 capsules given once daily for 42 days.

  • DrugCohort 1 CTAP101 Capsules - 90µg

    90µg of CTAP101 capsules given once daily for 42 days.

  • DrugCohort 1 Matching Sugar Capsule

    Placebo capsules given once daily for 42 days.

  • DrugCohort 2 CTAP101 Capsules - 30µg

    30µg of CTAP101 capsules given once daily for 42 days.

  • DrugCohort 2 Matching Sugar Capsule

    Placebo capsules given once daily for 42 days.

06

What researchers measure

Primary outcomes

  1. Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).

    The proportion of subjects in the per protocol population with serum 25-hydroxyvitamin D ≥30 ng/mL at End-of-Treatment (EOT; Week 6) in Cohorts 1 and 2 (60/90 and 30 μg groups, respectively) were compared to their corresponding placebo groups.

    Time frame: 6 weeks

  2. Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)

    Mean percent change from baseline in plasma intact parathyroid hormone (iPTH) from baseline to End of Treatment (EOT) in the Per Protocol population. Subjects in Cohorts 1 and 2 (dose regimens 60/90 and 30 mcg, respectively) were compared to their respective placebo groups.

    Time frame: 6 weeks

Secondary outcomes

  1. Change From Baseline in Serum 25-hydroxyvitamin D at Week 6

    Mean absolute change from baseline in serum total 25-hydroxyvitamin D to end of treatment (EOT)

    Time frame: Baseline to End of Treatment (6 weeks)

  2. Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population

    Mean percent change from baseline in serum 25-hydroxyvitamin D at End of Treatment (EOT, week 6) in the per protocol population. Subjects in Cohorts 1 and 2 (dose regimens of 60/90 and 30 mcg, respectively) were compared versus their corresponding placebo groups.

    Time frame: Baseline to End of Treatment (6 weeks)

  3. Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6

    Proportion of subjects with at least 30% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)

    Time frame: Baseline to End of Treatment (6 weeks)

  4. Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6

    Proportion of subjects with at least 20% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)

    Time frame: Baseline to End of Treatment (6 weeks)

07

Results

Posted Aug 25, 2016

Participant flow

Subjects with Stage 3 chronic kidney disease, vitamin D insufficiency and secondary parahyperthyroidism were recruited from 16 sites within the US.

Participant flow — Overall Study
MilestoneCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Started1717171314
Completed1612161213
Not completed15111

Outcome measures

PrimaryProportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).

The proportion of subjects in the per protocol population with serum 25-hydroxyvitamin D ≥30 ng/mL at End-of-Treatment (EOT; Week 6) in Cohorts 1 and 2 (60/90 and 30 μg groups, respectively) were compared to their corresponding placebo groups.

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).
percentage of participantsCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).100100091.77.1
Statistical analysis
  • Cohort 1: CTAP101 Capsules 60µg vs Cohort 1: CTAP101 Capsules 90µg vs Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Z-test cmpared 2 independ. proportions · p = <0.0001
PrimaryMean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)

Mean percent change from baseline in plasma intact parathyroid hormone (iPTH) from baseline to End of Treatment (EOT) in the Per Protocol population. Subjects in Cohorts 1 and 2 (dose regimens 60/90 and 30 mcg, respectively) were compared to their respective placebo groups.

Time frame:
6 weeks
Reported as:
Mean · percentage of change from baseline
Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)
percentage of change from baselineCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)-32.77 ± 22.778-39.32 ± 16.24320.49 ± 52.871-20.86 ± 21.54913.18 ± 30.185
Statistical analysis
  • Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Mixed effect model · p = <0.01
SecondaryChange From Baseline in Serum 25-hydroxyvitamin D at Week 6

Mean absolute change from baseline in serum total 25-hydroxyvitamin D to end of treatment (EOT)

Time frame:
Baseline to End of Treatment (6 weeks)
Reported as:
Mean · ng/mL
Change From Baseline in Serum 25-hydroxyvitamin D at Week 6
ng/mLCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Change From Baseline in Serum 25-hydroxyvitamin D at Week 643.25 ± 16.51963.69 ± 17.826-0.65 ± 2.50216.22 ± 6.005-1.89 ± 4.913
Statistical analysis
  • Cohort 1: CTAP101 Capsules 60µg vs Cohort 1: CTAP101 Capsules 90µg vs Cohort 1: Sugar Capsule vs Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Mixed effect model · p = <0.0001
  • Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Mixed effect model · p = <0.01
SecondaryPercent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population

Mean percent change from baseline in serum 25-hydroxyvitamin D at End of Treatment (EOT, week 6) in the per protocol population. Subjects in Cohorts 1 and 2 (dose regimens of 60/90 and 30 mcg, respectively) were compared versus their corresponding placebo groups.

Time frame:
Baseline to End of Treatment (6 weeks)
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population
percentage of change from baselineCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population187.64 ± 74.251313.12 ± 101.592-2.67 ± 13.06990.90 ± 62.189-7.22 ± 20.599
Statistical analysis
  • Cohort 1: CTAP101 Capsules 60µg vs Cohort 1: CTAP101 Capsules 90µg vs Cohort 1: Sugar Capsule vs Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Mixed effect model · p = <0.0001
SecondaryProportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6

Proportion of subjects with at least 30% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)

Time frame:
Baseline to End of Treatment (6 weeks)
Reported as:
Number · participants
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6
participantsCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6119250
Statistical analysis
  • Cohort 1: CTAP101 Capsules 60µg vs Cohort 1: CTAP101 Capsules 90µg vs Cohort 1: Sugar Capsule vs Cohort 2: CTAP101 Capsules 30µg vs Cohort 2: Sugar Capsule · Z-test compared 2 independ. proportions · p = <0.05
SecondaryProportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6

Proportion of subjects with at least 20% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)

Time frame:
Baseline to End of Treatment (6 weeks)
Reported as:
Number · participants
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6
participantsCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar Capsule
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 61213251
Statistical analysis
  • Cohort 1: CTAP101 Capsules 60µg vs Cohort 1: CTAP101 Capsules 90µg vs Cohort 1: Sugar Capsule · Z-test compared 2 independ. proportions · p = <0.001

Adverse events

Collected over 12 weeks (6 week treatment period, followed by 6 week follow-up period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohorts 1,2: Sugar Capsule—1/31 (3.2%)22/31 (71%)
Cohort 2: CTAP101 Capsules 30µg—1/13 (7.7%)8/13 (61.5%)
Cohort 1: CTAP101 Capsules 60µg—1/17 (5.9%)12/17 (70.6%)
Cohort 1: CTAP101 Capsules 90µg—1/16 (6.3%)10/16 (62.5%)
Most frequent serious events
Most frequent serious events
EventCohorts 1,2: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µg
Cardiac failure congestiveCardiac disorders0/311/130/171/16
Renal failure acuteRenal and urinary disorders0/311/130/170/16
AngioplastySurgical and medical procedures0/311/130/170/16
Acute prerenal failureRenal and urinary disorders0/310/130/171/16
Femoral neck fractureInjury, poisoning and procedural complications0/310/130/171/16
HypoglycaemiaEndocrine disorders0/310/131/170/16
HeadacheNervous system disorders1/310/130/170/16
Most frequent other events
Showing 10 of 92
Most frequent other events
EventCohorts 1,2: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µg
Abdominal discomfortGastrointestinal disorders1/312/131/170/16
HyperphosphatemiaMetabolism and nutrition disorders0/312/131/171/16
Oedema peripheralGeneral disorders3/310/130/172/16
ContusionInjury, poisoning and procedural complications3/310/130/172/16
ArthralgiaMusculoskeletal and connective tissue disorders0/310/131/172/16
HeadacheNervous system disorders2/310/131/172/16
GoutMetabolism and nutrition disorders2/310/131/172/16
ConstipationGastrointestinal disorders1/310/132/170/16
Coronary artery diseaseCardiac disorders0/311/130/170/16
PalpitationsCardiac disorders0/311/130/170/16

Baseline characteristics

Intent to treat population (excludes a single subject randomized to the 90 µg treatment arm who was lost to follow-up prior to receiving study drug)

Age, Continuous
Age, Continuous(years)Cohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar CapsuleTotal
Mean64.7 ± 9.2064.6 ± 11.4161.9 ± 17.7958.2 ± 16.1463.9 ± 11.4763.0 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: CTAP101 Capsules 60µgCohort 1: CTAP101 Capsules 90µgCohort 1: Sugar CapsuleCohort 2: CTAP101 Capsules 30µgCohort 2: Sugar CapsuleTotal
Female79137743
Male10746734
08

Study locations

1 site
  • OPKO Health, Inc
    Bannockburn, Illinois 60015, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 4 years 9 months after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2010
First posted
Oct 13, 2010
Start
Oct 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results delay requested
Sep 16, 2014
Results first posted
Aug 25, 2016
Last update
Aug 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01219855
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2010
Start date
Oct 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Aug 25, 2016
Last update
Aug 25, 2016

Study contacts

Joel Melnick, MD
study director · OPKO Health, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion